Genomic Deletion of a Long-Range Bone Enhancer Misregulates Sclerostin in Van Buchem Disease

Genome Research - United States
doi 10.1101/gr.3437105
Full Text
Abstract

Available in full text

Categories
Genetics
Date
Authors
Publisher

Cold Spring Harbor Laboratory

Related search

Association of Serum Sclerostin With Bone Sclerostin in Chronic Kidney Disease Is Lost in Glucocorticoid Treated Patients

Calcified Tissue International
EndocrinologyOrthopedicsSports MedicineMetabolismDiabetes
2018English

Long-Range Transcriptional Control of theIl2Gene by an Intergenic Enhancer

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2015English

Postnatal Skeletal Deletion of Dickkopf-1 Increases Bone Formation and Bone Volume in Male and Female Mice, Despite Increased Sclerostin Expression

Journal of Bone and Mineral Research
EndocrinologyOrthopedicsSports MedicineMetabolismDiabetes
2018English

Role of Sclerostin in the Pathogenesis of Chronic Kidney Disease-Mineral Bone Disorder

Renal Replacement Therapy
2016English

Novel Actions of Sclerostin on Bone

Journal of Molecular Endocrinology
EndocrinologyMolecular Biology
2019English

Enhancer-Like Long-Range Transcriptional Activation by CI-mediated DNA Looping

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2013English

Changes in Bone Sclerostin Levels in Mice After Ovariectomy Vary Independently of Changes in Serum Sclerostin Levels

Journal of Bone and Mineral Research
EndocrinologyOrthopedicsSports MedicineMetabolismDiabetes
2013English

Role and Mechanism of Action of Sclerostin in Bone

Bone
EndocrinologyPhysiologyHistologyMetabolismDiabetes
2017English

Localization of the Gene for Sclerosteosis to the Van Buchem Disease–Gene Region on Chromosome 17q12–q21

American Journal of Human Genetics
Genetics
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy